APVO · XBRL financial data
Aptevo Therapeutics financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (APVO's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue from contracts with customers | 4,309 | 12,292 | 3,114 | — | — | — |
| Research and development | 17,852 | 18,994 | 17,882 | 17,107 | 14,378 | 14,540 |
| General and administrative | 13,951 | 14,698 | 13,873 | 11,771 | 10,224 | 11,772 |
| Operating income (loss) | (27,494) | (21,400) | (28,641) | (28,878) | (24,602) | (26,312) |
| Other income (expense) | (1,325) | (8,008) | (4,027) | 578 | 472 | 345 |
| Income tax expense (benefit) | — | — | — | — | — | 0 |
| Net income (loss) | (17,750) | (28,457) | 8,027 | (17,411) | (24,130) | (25,967) |
| Earnings per share, basic‡ USD per share | — | (6,244,855,967.08) | 1,615,226,337.45 | (1,460,905,349.79) | (53,938,271.60) | (4,363.50) |
| Earnings per share, diluted‡ USD per share | — | (6,244,855,967.08) | 1,615,226,337.45 | (1,460,905,349.79) | (53,938,271.60) | (4,363.50) |
| Weighted average shares, basic‡ thousands of shares | — | 0 | 0 | 0 | 0 | 6 |
| Weighted average shares, diluted‡ thousands of shares | — | 0 | 0 | 0 | 0 | 6 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (March 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-33.333333333333336 stock split (December 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-37.03703703703704 stock split (December 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2025); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (June 2025); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-16.666666666666668 stock split (December 2025); filings made before it reported them unadjusted.
- † Share count changed about 11818x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (APVO's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 39,979 | 45,044 | 22,635 | 16,904 | 8,714 | 21,619 |
| Prepaid and other current assets | — | — | — | — | 1,945 | 1,462 |
| Total current assets | 47,264 | 52,570 | 27,450 | 19,066 | 10,659 | 23,081 |
| Property and equipment, net | 2,815 | 2,379 | 1,462 | 895 | 543 | 303 |
| Right-of-use asset | 2,722 | 1,584 | 5,303 | 4,881 | 4,389 | 3,810 |
| Total assets | 53,547 | 56,601 | 34,215 | 24,842 | 15,591 | 27,194 |
| Accounts payable | — | — | — | — | 1,242 | 877 |
| Current portion of long-term debt | 5,000 | 11,667 | 2,000 | — | — | — |
| Total current liabilities | 14,539 | 34,757 | 8,706 | 7,224 | 6,207 | 6,050 |
| Long-term debt | — | 3,707 | 1,456 | — | — | — |
| Lease liability, non-current | 2,360 | 1,341 | 6,079 | 5,397 | 4,629 | 3,763 |
| Total liabilities | 36,953 | 55,385 | 16,241 | 12,621 | 10,836 | 9,813 |
| Accumulated deficit | (185,606) | (214,063) | (206,036) | (223,447) | (247,577) | (275,115) |
| Total stockholders' equity | 16,594 | 1,216 | 17,974 | 12,221 | 4,755 | 17,381 |
| Total liabilities and equity | 53,547 | 56,601 | 34,215 | 24,842 | 15,591 | 27,194 |
| Common shares outstanding (cover page)‡ thousands of shares | 0 | 0 | 0 | 0 | 0 | 24 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (March 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-33.333333333333336 stock split (December 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-37.03703703703704 stock split (December 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (June 2025); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (June 2025); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-16.666666666666668 stock split (December 2025); filings made before it reported them unadjusted.
- † Share count changed about 11818x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (APVO's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | †Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (17,750) | (28,457) | 8,027 | (17,411) | (24,130) | (25,967) |
| Stock-based compensation | 1,255 | 1,643 | 1,802 | 2,193 | 1,069 | 96 |
| Depreciation and amortization | 1,406 | 1,144 | 901 | 567 | 352 | 240 |
| Net cash from operating activities | (29,318) | (21,679) | (21,022) | (11,730) | (23,785) | (25,592) |
| Purchases of property and equipment | 88 | 713 | 29 | — | — | — |
| Net cash from investing activities | 28,032 | (713) | (29) | 0 | 0 | 0 |
| Proceeds from issuing common stock | — | 10,233 | 6,934 | 6,428 | 10,036 | 37,940 |
| Repayments of long-term debt | 22,104 | 10,550 | 12,267 | 3,467 | 0 | — |
| Net cash from financing activities | 23,874 | 26,161 | (2,616) | 5,998 | 15,595 | 38,497 |
| Net change in cash | 22,588 | 3,769 | (23,667) | (5,732) | (8,190) | 12,905 |
- † Share count changed about 11818x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Aptevo Therapeutics | 9,797 | not reported | (5,454)* | 1.8M | 1.8 quarters | 10-QJun 30, 2026 |
| Traws Pharma | 5,016 | not reported | (7,504)* | 15.4M | 0.7 quarters | 10-QJun 30, 2026 |
| Mannatech | 6,034 | 26,650 | (792)* | 1.9M | 7.6 quarters | 10-QJun 30, 2026 |
| LeonaBio | 32,323 | not reported | (16,958)* | 9.4M | 3.0 quarters | 10-QJun 30, 2026 |
| BioCardia | 4,117 | not reported | (1,735)* | 15.1M | 2.4 quarters | 10-QJun 30, 2026 |
| Alaunos Therapeutics | 124 | 0 | (300)* | 2.5M | 0.4 quarters | 10-QJun 30, 2026 |
| Raphael Pharmaceutical | 1 | not reported | 0* | 20.2M | — | 10-QJun 30, 2026 |
| Scienture Holdings | 8,188 | 344 | (3,132)* | 41.1M | 2.6 quarters | 10-QJun 30, 2026 |
| Bioxytran | 177 | not reported | (350)* | 114.7M | 0.5 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.